DARENCT07538843
An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment
At risk: Primary completion moved 60 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 16 words
- Primary completion pushed from Nov 1, 2029 to Dec 31, 2029
- Secondary endpoints: details revised at 4 of 9 entries
- Site contact updated
- Notable Recruitment opened
- Start date changed from estimate of Jul 30, 2026 to Jul 31, 2026
- Site details revised
- Notable Start date: Jun 1, 2026 to Jul 30, 2026v3
- Notable Eligibility criteria shortened, about 1 wordv2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Proportion of patients with prostatic specific antigen (PSA) undetectable within 6 months (Master Cohort)
Timeframe: up to 6 months
Proportion of patients with PSA Progression Free Survival (PSA-PFS) rate at 12 months (Sub-cohort)
Timeframe: up to 12 months
Secondary (9)
Proportion of patients with PSA50 within 3 months (Master cohort)
Proportion of patients with PSA50 within 6 months (Master cohort)
Proportion of patients with PSA90 within 3 months (Master cohort)
Proportion of patients with PSA90 within 6 months (Master cohort)
Proportion of patients with PSA undetectable within 3 months (Master cohort)
Show 4 moreShow less
Proportion of patients with PSA50/90 within 12 months (Sub-cohort)
Proportion of patients with PSA undetectable within 12 months (Sub-cohort)
Metastasis-free survival (MFS) rate at 12 months (Sub-cohort)
Proportion of patients with Treatment Emergent Adverse Events (Master and Sub-cohort)
Arms and interventions
Master-cohort (6 months follow-up)
Male patients receiving ADT+Bicalutamide for ≥ 6 months in non-metastatic hormone-sensitive prostate cancer (nmHSPC), that progressed to non-metastatic castration-resistant prostate cancer (nmCRPC)
Sub-cohort (12 months follow-up)
Male patients receiving ADT+Bicalutamide for ≥ 6 months in non-metastatic hormone-sensitive prostate cancer (nmHSPC), that progressed to non-metastatic castration-resistant prostate cancer (nmCRPC)
Drugs: Darolutamide, ADT
Sites
1 site in 1 country
- Many locationsMultiple Locations, China